XML 38 R27.htm IDEA: XBRL DOCUMENT v3.25.3
Summary of Significant Accounting Policies - Schedule of Basic and Diluted Net Income (Loss) Per Ordinary Share (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Class A – Public shares [Member]        
Numerator:        
Allocation of net income (loss) $ 2,169,987 $ 1,595,961
Denominator:        
Basic weighted average number of ordinary shares outstanding 27,600,000 9,705,495
Diluted weighted average number of ordinary shares outstanding 27,600,000 9,705,495
Basic net income (loss) per ordinary share $ 0.08 $ 0.16
Diluted net income (loss) per ordinary share $ 0.08 $ 0.16
Class A – Private placement shares [Member]        
Numerator:        
Allocation of net income (loss) $ 45,601 $ 33,538
Denominator:        
Basic weighted average number of ordinary shares outstanding 580,000 203,956
Diluted weighted average number of ordinary shares outstanding 580,000 203,956
Basic net income (loss) per ordinary share $ 0.08 $ 0.16
Diluted net income (loss) per ordinary share $ 0.08 $ 0.16
Class B – Ordinary shares [Member]        
Numerator:        
Allocation of net income (loss) $ 542,497 $ (40,040) $ 1,038,676 $ (42,920)
Denominator:        
Basic weighted average number of ordinary shares outstanding 6,900,000 6,000,000 [1] 6,316,484 [1] 6,000,000 [1],[2]
Diluted weighted average number of ordinary shares outstanding 6,900,000 6,000,000 6,316,484 6,000,000
Basic net income (loss) per ordinary share $ 0.08 $ (0.01) $ 0.16 $ (0.01)
Diluted net income (loss) per ordinary share $ 0.08 $ (0.01) $ 0.16 $ (0.01)
[1] This number has been retroactively adjusted to reflect the capitalization of the Company in the form of the issuance of 750,000 and 1,150,000 Class B ordinary shares on June 15, 2025 and June 25, 2025, respectively (See Note 7).
[2] This number has been retroactively adjusted to reflect the recapitalization of the Company in the form of the cancellation of 9,375,000 Class B ordinary shares on June 6, 2024 (See Note 7).